New stimulant EB-1020 put to the test: will it be abused?
NCT ID NCT02144415
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether a new drug called EB-1020 has abuse potential in 80 healthy adults who use stimulants recreationally. Participants received single doses of EB-1020, d-amphetamine, or placebo, and rated how much they liked the drug. The goal was to see if EB-1020 produces a 'high' similar to other stimulants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- EB-1020 immediate-release capsules
- What this could lead to
- If EB-1020 shows low abuse potential, it may be developed as a safer stimulant alternative for conditions like ADHD.
- What could go wrong
- This is an early Phase 1 study in healthy volunteers, not patients. The results may not predict real-world abuse or effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRUG USERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Vince and Associates Clinical Research, Inc.
Overland Park, Kansas, 66212, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults